Valuation: Regeneron Pharmaceuticals, Inc.

Market Cap 75.81B 65.89B 61.52B 56.47B 106B 7,226B 108B 725B 284B 3,604B 285B 278B 11,886B P/E 2026 *
18x
P/E 2027 * 15.1x
Enterprise Value 68.95B 59.92B 55.94B 51.36B 96.84B 6,572B 98.52B 660B 258B 3,277B 259B 253B 10,809B EV / Sales 2026 *
4.08x
EV / Sales 2027 * 3.56x
Free-Float
73.31%
Yield 2026 *
0.51%
Yield 2027 * 0.58%
1 day-0.44%
1 week+13.80%
Current month-0.44%
1 month+16.04%
3 months+8.24%
6 months+0.01%
Current year-1.64%
1 week 691
Extreme 691
772.75
1 month 637.72
Extreme 637.715
772.75
Current year 591.52
Extreme 591.52
821.11
1 year 541
Extreme 541
821.11
3 years 476.49
Extreme 476.4869
1,211.2
5 years 476.49
Extreme 476.4869
1,211.2
10 years 271.37
Extreme 271.37
1,211.2
Manager TitleAgeSince
President 66 01/01/2001
Chief Executive Officer 73 08/01/1988
Director of Finance/CFO 55 05/02/2024
Director TitleAgeSince
Chairman 73 09/06/2023
Director/Board Member 85 01/06/1991
Director/Board Member 85 01/06/1991
Date Insider Type Main position Quantity % Market Cap.
2/7/26 Sell

Director

-200 0.0002%
19/2/26 Fiscal year

Director

4,914 0.0048%
9/2/26 Fiscal year

SVP Controller

4,036 0.0039%
Change 5-day change 1-year change 3-year change Capi.($)
-0.44%+13.80%+35.85%-1.58% 76.15B
-0.67%-9.93%+19.77%+179.40% 48.89B
-4.18%+42.30%+42.30%+42.30% 47.83B
+2.00%+6.16%-52.10%-52.15% 41.37B
-0.56%+0.84%+52.95%-24.62% 29.99B
-0.91%-0.37%+56.67%+82.26% 24.23B
+0.58%-0.88%+99.75%-49.85% 21.89B
-0.06%-4.51%-7.59%+161.74% 19.25B
-7.35%-6.03%+64.90%+113.10% 17.14B
-0.16%-4.95%+68.80%+149.10% 15.66B
Average -1.18%-0.26%+38.13%+59.97% 34.24B
Weighted average by Cap. -0.99%+1.16%+31.40%+46.92%

Financials

2026 *2027 *
Net sales 16.9B 14.69B 13.71B 12.59B 23.74B 1,611B 24.15B 162B 63.33B 803B 63.48B 62.08B 2,650B 18.31B 15.91B 14.86B 13.64B 25.72B 1,745B 26.17B 175B 68.61B 870B 68.78B 67.26B 2,871B
Net income 4.61B 4B 3.74B 3.43B 6.47B 439B 6.58B 44.07B 17.26B 219B 17.3B 16.92B 722B 5.35B 4.65B 4.34B 3.99B 7.52B 510B 7.65B 51.21B 20.06B 254B 20.11B 19.66B 839B
Net Debt -6.87B -5.97B -5.57B -5.12B -9.65B -655B -9.81B -65.71B -25.74B -326B -25.8B -25.23B -1,077B -10.55B -9.17B -8.56B -7.86B -14.82B -1,006B -15.08B -101B -39.55B -502B -39.64B -38.76B -1,655B
Logo Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Net sales break down by type of revenue as follows: - revenues from collaboration agreements (51.1%): collaboration with Sanofi (80.3% of revenues), Bayer (19.4%) and other (0.3%); - revenues from product sales (30%); - revenues from sales of technology licenses and subcontracted research services (4.9%). At the end of 2025, the group had a portfolio of approximately 45 products in clinical development.
Employees
15,410
Date Price Change Volume
03/08/26 USD 759.24 -0.44% 842,623
31/07/26 USD 762.63 +3.29% 1,158,583
30/07/26 USD 738.34 +6.17% 1,460,963
29/07/26 USD 695.42 +0.03% 1,022,421
28/07/26 USD 695.18 +4.20% 900,408
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
27
Last Close Price
759.24USD
Average target price
833.54USD
Spread / Average Target
+9.79%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. REGN Stock